
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neonatology</journal-id><journal-id journal-id-type="iso-abbrev">Neonatology</journal-id><journal-id journal-id-type="publisher-id">NEO</journal-id><journal-title-group><journal-title>Neonatology</journal-title></journal-title-group><issn pub-type="ppub">1661-7800</issn><issn pub-type="epub">1661-7819</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18776731</article-id><article-id pub-id-type="pmc">2863292</article-id><article-id pub-id-type="doi">10.1159/000153101</article-id><article-id pub-id-type="publisher-id">neo-0095-0164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Characterization and Differentiation of Iron Status in Anemic Very Low Birth Weight Infants Using a Diagnostic Nomogram</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kasper</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Widness</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haiden</surname><given-names>Nadja</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Angelika</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hayde</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pollak</surname><given-names>Arnold</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Herkner</surname><given-names>Kurt R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria</aff><aff id="aff2"><sup>b</sup>Research Core Unit of Pediatric Biochemistry and Analytics, Medical University of Vienna, Vienna, Austria</aff><aff id="aff3"><sup>c</sup>Department of Pediatrics, College of Medicine, University of Iowa, Iowa City, Iowa, USA</aff><author-notes><corresp id="cor1">*David C. Kasper, MSc, PhD, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Waehringer Guertel 18&#x02013;20, AT&#x02013;1090 Vienna (Austria), Tel. +43 1 40400 2756, Fax +43 1 40400 3200, E-Mail <email>david.kasper@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>9</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2010</year></pub-date><!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. --><volume>95</volume><issue>2</issue><fpage>164</fpage><lpage>171</lpage><history><date date-type="received"><day>17</day><month>9</month><year>2007</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 by S. Karger AG, Basel</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://www.karger.com/Authors_Choice"><license-p>This is an open access article distributed under the terms of Karger's Author's Choice&#x02122; licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged.</license-p></license></permissions><abstract><sec><title>Background</title><p>In the early weeks of life, very low birth weight (VLBW) infants experience intense laboratory blood sampling leading to clinically significant anemia and the need for red blood cell transfusion. Although controversial, treatment with recombinant human erythropoietin (EPO) and iron has been recommended to stimulate erythropoiesis; optimal dosing of EPO and iron is still uncertain. <italic>Objectives:</italic> To assess the validity of a four-quadrant diagnostic plot of iron availability (ferritin index) versus iron demand for erythropoiesis (reticulocyte hemoglobin content, CHr) for differentiating iron status in anemic VLBW infants.</p></sec><sec><title>Methods</title><p>Study subjects were enrolled in a previously reported randomized controlled trial of clinically stable VLBW infants &#x0003c;31 weeks&#x02019; gestation and &#x0003c;1,300 g at birth to receive 18 days of treatment with: group 1: oral iron; group 2: EPO + oral iron, and group 3: EPO + intravenous + oral iron.</p></sec><sec><title>Results</title><p>At the end of treatment the ferritin index was significantly higher in both EPO groups compared to the control group. By day 18, CHr of the control group declined into the quadrant of the diagnostic plot characteristic of functional iron deficiency and anemia of chronic disease. Both EPO groups ended in the quadrants that are characteristic for latent iron deficiency and iron deficiency anemia, respectively.</p></sec><sec><title>Conclusions</title><p>The diagnostic plot for differentiating anemia in VLBW infants may be an informative, clinically useful tool for iron status assessment under different physiologic and therapeutic erythropoietic states. Larger additional studies in difficult patient populations are needed before the clinical utility of this diagnostic procedure can be unequivocally confirmed.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>VLBW infants</kwd><kwd>Diagnostic plot</kwd><kwd>Ferritin index</kwd><kwd>sTfR</kwd><kwd>CHr</kwd><kwd>Iron deficiency</kwd><kwd>Erythropoiesis</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><ref-count count="30"/><page-count count="8"/></counts></article-meta></front><body><sec id="sec1_1"><title>Introduction</title><p>Very low birth weight (VLBW) infants commonly receive one or more red blood cell (RBC) transfusions during their first months of life [<xref ref-type="bibr" rid="B1">1</xref>]. In the majority of preterm infants, anemia is a result of multiple factors which include iatrogenic blood loss, inadequate RBC production, shorter RBC lifespan, insufficient iron stores, and rapid growth [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Recombinant human erythropoietin (r-HuEPO) therapy has been suggested as an alternative to RBC transfusion in the treatment of neonatal anemia. Although meta-analysis of controlled clinical studies has shown some benefit in the prevention of RBC transfusions even in extremely low birth weight infants (&#x0003c;1,000 g) [<xref ref-type="bibr" rid="B5">5</xref>], treatment of anemia of prematurity (AOP) with r-HuEPO remains controversial [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. This controversy has in part focused on conflicting strategies concerning what constitutes optimal iron supplementation during r-HuEPO treatment of anemic infants, i.e. identification of an r-HuEPO and iron-dosing schedule that provides adequate available iron to meet the needs of accelerated erythropoiesis while avoiding the risk of iron toxicity.</p><p>Unfortunately, characterization of iron-deficient states in infants is challenging. In addition to traditional parameters such as complete blood countand biochemical markers of iron metabolism, e.g., serum transferrin, transferrin saturation and serum ferritin, more recent parameters used in defining iron status and iron-deficient states include zinc erythrocyte protoporphyrin, soluble transferrin receptor (sTfR), and the ferritin index (FI) [<xref ref-type="bibr" rid="B9">9</xref>]. Zinc erythrocyte protoporphyrin is non-specific since its levels increase either when erythropoiesis is stimulated or when early functional iron deficiency (FID) is present. The interpretation of both sTfR and the FI is useful in the evaluation of iron status and erythropoietic activity as shown by Dimitriou et al. [<xref ref-type="bibr" rid="B9">9</xref>] in children and neonates. High sTfR levels indicate increased iron demand when iron stores are being depleted. Consequently the measurement of sTfR is helpful for investigating the pathophysiology of anemia by allowing the evaluation of the adequacy of marrow proliferative capacity and the erythropoietic response to various therapies [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Recently, the combination of hemoglobin content of reticulocytes (CHr), an early indicator of iron demand, and FI have been investigated by Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>] as promising diagnostic tools for classifying and monitoring of iron deficiency in the anemia of chronic disease (ACD) in adult cancer patients. Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>] speculated that the diagnostic plot might also be a useful tool in assessing iron status in a broad spectrum of other anemias, including classical iron deficiency, end-stage renal failure and anemia of infection and inflammation. These investigators have devised a promising method for describing the relationship of FID (represented by CHr) to the availability of iron for erythropoiesis (represented by FI). These authors used a plot of these two variables to describe this relationship. Doing so offers the advantage of classifying iron deficiency into four discrete states (fig. <xref ref-type="fig" rid="F1">1</xref>): quadrant 1 (Q1) indicates full or replete iron stores, quadrant 2 (Q2) indicates unsatisfactory iron stores prior to iron-deficient erythropoiesis &#x02013; latent iron deficiency, quadrant 3 (Q3) indicates depletion of iron storages and decreased hemoglobinization of red cells &#x02013; iron deficiency anemia, and quadrant 4 (Q4) indicates full or replete iron stores but inappropriate iron metabolism &#x02013; FID. This plot offers the potential for monitoring erythropoietic activity, FID and the adequacy of iron availability for EPO-stimulated RBC production.</p><p>The aim of the study was to apply the diagnostic plot to the results of a previous study of r-HuEPO and iron-treated VLBW infants to assess whether this diagnostic tool is suitable for differentiating iron-deficient stages in AOP [<xref ref-type="bibr" rid="B3">3</xref>]. We hypothesized that the information derived has potential for being useful in therapeutic decision-making regarding the need for iron replacement and/or r-HuEPO therapy in anemic infants.</p></sec><sec sec-type="methods" id="sec1_2"><title>Methods</title><sec id="sec2_1"><title>Participants and Study Design</title><p>Using the diagnostic plot to assess iron status relative to r-HuEPO and iron therapy, we retrospectively analyzed previously described data from a randomized controlled trial from clinically stable VLBW infants &#x0003c;31 weeks of gestation and &#x0003c;1,300 g birth weight [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>In brief, inclusion criteria postnatal age &#x0003e;1 week, hematocrit &#x0003e;30%, phlebotomy loss averaging &#x0003c;1.0 ml/day over the previous 3 days, enteral caloric intake &#x0003e;20 kcal/kg/day and stable respiratory status defined as mean oxygen saturation &#x0003e;90% in a fraction of inspired oxygen &#x02264;0.40 for &#x0003e;48 h regardless of ventilation. Infants excluded were those who received RBC transfusions 3 days before study entry or during the study, those with an active, culture-proven infection, a major malformation, electroencephalographic-proven seizures, hypertension, intraventricular hemorrhage &#x02265; grade III, immune hemolytic disease, necrotizing enterocolitis, or surgery. Among the study participants who began the study, 3 infants with sepsis or sepsis-like episodes, 2 with necrotizing enterocolitis, 2 who received RBC transfusions were excluded.</p><p>There were no statistical differences among the three study groups for common neonatal morbidities including respiratory distress syndrome (p = 0.65), bronchopulmonary dysplasia (oxygen dependency at 36 weeks of postconceptional age; p = 0.31), patent ductus arteriosus (p = 0.60) and retinopathy of prematurity (p = 0.32). There were also no significant differences identified among the three study groups for birth weight or in age, body weight, or phlebotomy loss at the prior to and during the treatment period (table <xref ref-type="table" rid="T1">1</xref>).</p><p>The 21-day study consisted of a 3-day run-in baseline period during which all subjects received 9 mg/kg/day of iron polymaltose complex (IPC; Ferrum Hausmann Syrup, Vifor International, St. Gallen, Switzerland). To remain in the study, subjects were not allowed to receive treatment with RBC transfusion. Study participants were randomized to receive 18 days of oral iron alone (group 1: oral iron; control group), r-HuEPO + oral iron (group 2: EPO + oral iron), or r-HuEPO + intravenous (IV) iron (group 3: EPO + IV iron) treatment beginning after a 3-day run-in period (table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec id="sec2_2"><title>Analytical Procedures</title><p>Hematological parameters and the iron status (sTfR, ferritin) were determined on peripheral venous or arterial blood drawn on treatment days &#x02212;3, 0, 4, 11, and 18. Hematological parameters were analyzed immediately. Serum and plasma were aliquoted and stored at &#x02212;80&#x000b0;C for later analysis. Blood counts, reticulocyte counts, RBC and CHr indices were performed on fresh whole blood samples by flow cytometry (Technicon H.3 Autoanalyzer, Bayer Austria GmbH, Vienna, Austria). Ferritin was determined by a radioimmunoassay (Bio-Rad Quantimmune Ferritin IRMA, Bio-Rad Diagnostics Group, Hercules, Calif., USA). Transferrin was measured by an antigen-antibody turbidimetric method using rabbit human transferrin antiserum (Boehringer Mannheim, Indianapolis, Ind., USA). sTfR concentration was determined by an ELISA (Ramco Laboratories, Inc., Houston, Tex., USA). The FI was calculated using the following equation: sTfR [mg/l]/log ferritin [&#x003bc;g/l] [<xref ref-type="bibr" rid="B9">9</xref>].</p></sec><sec id="sec2_3"><title>Statistical Analyses</title><p>Within-group comparisons were performed by paired-samples t test (two-tailed). Between-group comparisons were performed by independent-samples t test and ANOVA with Bonferroni posthoc multiple comparisons test for normal distributed data or Mann-Whitney U test for non-parametric sample distribution. Results are expressed as mean &#x000b1; SEM. p &#x0003c; 0.05 was considered statistically significant. Calculations were done with SPSS 14.0 (SPSS, Inc., Chicago, Ill., USA).</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>The age of subjects at study entry was 23 &#x000b1; 2.9 days. Demographic and clinical features of the three study groups including gestational age and birth weight have been described previously and did not differ among the three groups at treatment day &#x02212;3 or baseline. On day 0, none of the hematological or serological parameters demonstrated significance between group differences (table <xref ref-type="table" rid="T3">3</xref>) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>As anticipated, subsequent hematological and serological parameters demonstrated significant differences among the groups according to their therapeutic assignment (fig. <xref ref-type="fig" rid="F2">2a&#x02013;c</xref>). Posttreatment changes in sTfR concentration were significantly higher in group 2 (EPO + oral iron) and group 3 (EPO + IV iron) compared to group 1 (oral iron; control group) (p &#x0003c; 0.01; fig. <xref ref-type="fig" rid="F2">2a</xref>). The sTfR values increased significantly from baseline in both EPO groups on days 11 and 18 compared to the control group. Similarly, there was a posttreatment increase in the FI for both EPO groups starting at day 11 (p &#x0003c; 0.05) compared to the control group (fig. <xref ref-type="fig" rid="F2">2b</xref>). A significant increase in CHr occurred at day 18 (p &#x0003c; 0.05) in group 2, while in group 3 only a trend toward higher CHr values was observed which did not quite achieve statistical significance (p = 0.059) (fig. <xref ref-type="fig" rid="F2">2c</xref>).</p><p>Beginning on treatment day &#x02212;3 and continuing to day 18 at the end of treatment, serial iron status laboratory data for each group were plotted (CHr vs. FI; fig. <xref ref-type="fig" rid="F3">3</xref>) according to the method of Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>]. As the study period progressed, the pattern of laboratory findings of group 1 infants differed significantly in the course of CHr and FI in comparison to both r-HuEPO-treated groups. For group 1 infants, CHr by the end of study declined into Q4, the quadrant is indicative of functional iron-deficient anemia, e.g., for ACD. In contrast, the two r-HuEPO-treated groups moved to the right, i.e. an increase in FI was observed. Although the courses of group 2 and group 3 paralleled one another over time beginning with the initiation of r-HuEPO treatment, on day 18, group 2 infants (EPO and oral iron) ended up in Q2 (latent iron deficiency) while group 3 IV EPO + IV iron-treated infants ended in Q3 (iron-deficient anemia).</p></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>The aim of the present study was to examine the clinical utility of using a diagnostic plot of Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>] to assess iron availability for erythropoiesis in VLBW infants with AOP as an informative tool for clinicians. The data analyzed were derived from a previous study of VLBW premature infants treated with two different r-HuEPO and iron-dosing regimens used in the treatment of AOP. This diagnostic plot utilizes two sensitive and specific parameters of the adequacy of iron for erythropoiesis for the x- and y-axes: FI and CHr. The CHr and the FI were used as the key hematological indicators for the intensity of the demand for iron and the adequacy of iron supply, respectively. The plot was used to identify the initial and subsequent erythropoietic and iron status of the three study groups that differed in the r-HuEPO and oral and parenteral iron supplementation each received. CHr has been used in the diagnosis of different iron-deficient states and in the response to iron and/or r-HuEPO treatment [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Importantly, CHr provides a direct assessment of the incorporation of iron into erythrocyte hemoglobin and thus serves as a direct indicator of the recent functional availability of iron for the erythron [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. sTfR and zinc erythrocyte protoporphyrin were proposed as useful indicators for iron deficiency [<xref ref-type="bibr" rid="B19">19</xref>], because both parameters are directly associated with erythropoietic activity [<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. Both have therefore been used to help identifying iron deficiency states in children [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. The acute-phase reactant, ferritin, has primarily been used as an indicator of iron storage [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. In the absence of inflammatory disease, the sTfR to ferritin ratio (FI) is inversely correlated with iron stores in various anemic states, including the ACD and FID [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>In the previous study from which the present data were derived, we investigated the efficacy and safety of high doses of EPO/iron therapy on the AOP [<xref ref-type="bibr" rid="B3">3</xref>]. In our application of the diagnostic plot of Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>] to the present data beginning on day &#x02212;3, all three groups started in the upper left quadrant (Q1) of the plot (fig. <xref ref-type="fig" rid="F3">3</xref>), i.e. indicating that baseline iron status of all three groups were adequate relative to their erythropoietic demand. We speculate that the control group became increasingly anemic as a result of multiple factors impacting iron status including: (1) low endogenous EPO production, (2) diminished iron stores as a result of rapid growth, and (3) on going phlebotomy loss. We further speculated that the later two of these contributed to the decrease of CHr observed in the control group despite receiving oral iron supplementation.</p><p>Without administration of EPO, the course of the control group fell into the lower left quadrant (Q4) of the diagnostic plot and remained there until the end of the treatment period on day 18. Q4 is characteristic of anemic conditions associated with FID/ACD. These results suggest that the group 1 control subjects receiving oral iron supplementation alone experienced both r-HuEPO and iron deficiency by the end of the study. This unanticipated finding that control group infants moved from their initial position in iron sufficient Q1 to their final position at the end of the study in Q4, characteristic of anemic conditions associated with FID/ACD, is consistent with the findings of Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>]. On this point, we speculate that because the control group did not receive r-HuEPO treatment, iron was not incorporated in adequate amounts by reticulocytes. As a result, mean CHr values for control subjects fell below the 28 pg cutoff value for Q4. Thus, although iron stores were replete based on ferritin at treatment day 18 &#x0003e;200 &#x003bc;l/l and a FI &#x0003c;1.5, complete hemoglobinization did not occur. As such, treatment with r-HuEPO and additional iron supplementation might be considered as possible therapeutic considerations.</p><p>In contrast to the control group, both r-HuEPO-treated groups had moved into quadrant Q2 by treatment day 11. This can be interpreted as a successful response to the r-HuEPO therapy with a pronounced stimulation of erythropoiesis by the second week of treatment. No significant increase in CHr was observed in the EPO + IV iron group (p = 0.059) by day 18, while in the EPO + oral iron group a slight, but significant, increase in CHr was observed compared to the control group (p &#x0003c; 0.05). Based on our diagnostic plot data and the recent review of iron supplementation in preterm infants by of Ridley et al. [<xref ref-type="bibr" rid="B27">27</xref>], it can be hypothesized that oral iron supplementation together with EPO therapy is adequate clinical therapy for preterm infants during their period of AOP which is in accordance with the considerations of Ridley et al. [<xref ref-type="bibr" rid="B27">27</xref>]. By day 18, the course of group 2 ended in Q2, reflecting a latent iron deficiency. In contrast, the course of group 3 ended in Q3, indicative of classic iron deficiency anemia. Additional trials are needed to assess whether r-HuEPO administration might be stopped at this point and if iron therapy (oral and/or IV iron) alone is sufficient as a therapeutic intervention for patients entering Q2 or Q4 of the diagnostic plot.</p><p>The diagnostic plot has served as a clinically useful tool in evaluating iron status of patients with renal anemia in which CHr provides helpful information regarding FID in dialysis patients receiving erythropoiesis-stimulating agents [<xref ref-type="bibr" rid="B28">28</xref>]. The diagnostic plot also appears helpful in monitoring iron therapy in cancer-related anemia [<xref ref-type="bibr" rid="B11">11</xref>]. Treatment of preterm infants with EPO and iron is one therapeutic approach for AOP exacerbated by phlebotomy (and therefore iron) loss. The diagnostic plot might also be helpful as a supporting diagnostic tool for clinicians seeking to identify the optimal r-HuEPO and iron-dosing regimens. The influence of supplementation with vitamin B<sub>12</sub> and folic acid with or without r-HuEPO treatment and with IV iron to reduce the need for RBC transfusion [<xref ref-type="bibr" rid="B29">29</xref>] is another example of a clinical situation that would be of interest to apply the diagnostic plot to determine if a positive effect in the stimulation of erythropoiesis is observed. A clinical study by Worthington-White et al. [<xref ref-type="bibr" rid="B30">30</xref>] indicated that premature infants require additionally vitamin B<sub>12</sub> and folate, and it could be shown that the severity of anemia was reduced. In their study, infants treated with vitamin B<sub>12</sub> alone or combined with folate had higher hemoglobin values than the untreated (p &#x0003c; 0.0005) or solely folate-treated (p &#x0003c; 0.01) groups. In future studies, it will be important to include untreated infants starting at birth when both ferritin and sTfR levels are normally (i.e., in the absence of r-HuEPO and IV iron treatment and before receiving RBC transfusions) at their highest.</p></sec><sec sec-type="conclusions" id="sec1_5"><title>Conclusion</title><p>Our results indicate that the diagnostic plot developed by Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>] offers promise as a useful tool for assessing iron status in anemic preterm infants. In its reliance on laboratory determinations performed in most hospital laboratories, the diagnostic plot has the potential for providing a readily available, real-time indicator of iron status. This has particular relevance for anemic, rapidly growing low birth weight infants during treatment with erythropoiesis-stimulating factors which result in different degrees of iron demand for hemoglobin synthesis. Additional studies carried out in a robust spectrum of clinical circumstances and other neonatal patient groups are needed before the clinical utility of this new diagnostic procedure can be unequivocally relied on.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported in part by March of Dimes (Grant FY 95-0220), by Vifor International, St. Gallen, Switzerland, Janssen-Cilag Pharma (Vienna, Austria), and the Verein &#x02018;Unser Kind&#x02019;. The authors acknowledge the careful data and sample collection of Maria Babich, RN, the expert technical support of Robert L. Schmidt and Ron Rogers. The study was facilitated by the enthusiastic support of the nursing and physician staff of the Department of Pediatrics, University of Vienna. Most importantly, we thank the families who entrusted us with the care of their infants.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>EF</given-names></name><name><surname>Strauss</surname><given-names>RG</given-names></name><name><surname>Widness</surname><given-names>JA</given-names></name><name><surname>Mahoney</surname><given-names>LT</given-names></name><name><surname>Mock</surname><given-names>DM</given-names></name><name><surname>Seward</surname><given-names>VJ</given-names></name><name><surname>Cress</surname><given-names>GA</given-names></name><name><surname>Johnson</surname><given-names>KJ</given-names></name><name><surname>Kromer</surname><given-names>IJ</given-names></name><name><surname>Zimmerman</surname><given-names>MB</given-names></name></person-group><article-title>Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants</article-title><source>Pediatrics</source><year>2005</year><volume>115</volume><fpage>1685</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">15930233</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohler</surname><given-names>T</given-names></name><name><surname>Leo</surname><given-names>A</given-names></name><name><surname>Stadler</surname><given-names>A</given-names></name><name><surname>Linderkamp</surname><given-names>O</given-names></name></person-group><article-title>Mechanical fragility of erythrocyte membrane in neonates and adults</article-title><source>Pediatr Res</source><year>1992</year><volume>32</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">1635851</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollak</surname><given-names>A</given-names></name><name><surname>Hayde</surname><given-names>M</given-names></name><name><surname>Hayn</surname><given-names>M</given-names></name><name><surname>Herkner</surname><given-names>K</given-names></name><name><surname>Lombard</surname><given-names>KA</given-names></name><name><surname>Lubec</surname><given-names>G</given-names></name><name><surname>Weninger</surname><given-names>M</given-names></name><name><surname>Widness</surname><given-names>JA</given-names></name></person-group><article-title>Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants</article-title><source>Pediatrics</source><year>2001</year><volume>107</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11134438</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widness</surname><given-names>JA</given-names></name></person-group><article-title>Pathophysiology, diagnosis, and prevention of neonatal anemia</article-title><source>Neoreviews</source><year>2000</year><volume>1</volume><fpage>e61</fpage><lpage>e68</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>RF</given-names></name><name><surname>Obladen</surname><given-names>M</given-names></name><name><surname>Muller-Hansen</surname><given-names>I</given-names></name><name><surname>Kattner</surname><given-names>E</given-names></name><name><surname>Merz</surname><given-names>U</given-names></name><name><surname>Arlettaz</surname><given-names>R</given-names></name><name><surname>Groneck</surname><given-names>P</given-names></name><name><surname>Hammer</surname><given-names>H</given-names></name><name><surname>Kossel</surname><given-names>H</given-names></name><name><surname>Verellen</surname><given-names>G</given-names></name><name><surname>Stock</surname><given-names>GJ</given-names></name><name><surname>Lacaze-Masmonteil</surname><given-names>T</given-names></name><name><surname>Claris</surname><given-names>O</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Matis</surname><given-names>J</given-names></name><name><surname>Gilberg</surname><given-names>F</given-names></name></person-group><article-title>Early treatment with erythropoietin &#x003b2; ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1,000 g</article-title><source>J Pediatr</source><year>2002</year><volume>141</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12091844</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonell-Estrany</surname><given-names>X</given-names></name><name><surname>Figueras-Aloy</surname><given-names>J</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names></name></person-group><article-title>Erythropoietin and prematurity &#x02013; where do we stand?</article-title><source>J Perinat Med</source><year>2005</year><volume>33</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16207112</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aher</surname><given-names>S</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name></person-group><article-title>Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><volume>3</volume><fpage>CD004868</fpage><pub-id pub-id-type="pmid">16856064</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aher</surname><given-names>SM</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name></person-group><article-title>Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><volume>3</volume><fpage>CD004865</fpage><pub-id pub-id-type="pmid">16856063</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriou</surname><given-names>H</given-names></name><name><surname>Stiakaki</surname><given-names>E</given-names></name><name><surname>Markaki</surname><given-names>EA</given-names></name><name><surname>Bolonaki</surname><given-names>I</given-names></name><name><surname>Giannakopoulou</surname><given-names>C</given-names></name><name><surname>Kalmanti</surname><given-names>M</given-names></name></person-group><article-title>Soluble transferrin receptor levels and soluble transferrin receptor/log ferritin index in the evaluation of erythropoietic status in childhood infections and malignancy</article-title><source>Acta Paediatr</source><year>2000</year><volume>89</volume><fpage>1169</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">11083370</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beguin</surname><given-names>Y</given-names></name></person-group><article-title>Soluble transferrin receptor for the evaluation of erythropoiesis and iron status</article-title><source>Clin Chim Acta</source><year>2003</year><volume>329</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12589962</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Kirschbaum</surname><given-names>A</given-names></name><name><surname>Boehm</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name></person-group><article-title>The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy</article-title><source>Med Oncol</source><year>2006</year><volume>23</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16645227</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name></person-group><article-title>Anemia of chronic disease: pathophysiology and laboratory diagnosis</article-title><source>Lab Hematol</source><year>2005</year><volume>11</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15790548</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugnara</surname><given-names>C</given-names></name><name><surname>Schiller</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>J</given-names></name></person-group><article-title>Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states</article-title><source>Clin Lab Haematol</source><year>2006</year><volume>28</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">16999719</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Armsby</surname><given-names>C</given-names></name><name><surname>Rieber</surname><given-names>S</given-names></name><name><surname>Wingerter</surname><given-names>S</given-names></name><name><surname>Brugnara</surname><given-names>C</given-names></name><name><surname>Shapiro</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>H</given-names></name></person-group><article-title>Screening healthy infants for iron deficiency using reticulocyte hemoglobin content</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>924</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">16118382</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name></person-group><article-title>Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency</article-title><source>Clin Chem</source><year>2002</year><volume>48</volume><fpage>1066</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">12089176</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugnara</surname><given-names>C</given-names></name></person-group><article-title>Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function</article-title><source>Crit Rev Clin Lab Sci</source><year>2000</year><volume>37</volume><fpage>93</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">10811141</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugnara</surname><given-names>C</given-names></name></person-group><article-title>Iron deficiency and erythropoiesis: new diagnostic approaches</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><fpage>1573</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">14500582</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugnara</surname><given-names>C</given-names></name></person-group><article-title>Erythrocyte membrane transport physiology</article-title><source>Curr Opin Hematol</source><year>1997</year><volume>4</volume><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">9107529</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JW</given-names></name></person-group><article-title>Sensitivity, specificity, and predictive value of serum soluble transferrin receptor at different stages of iron deficiency</article-title><source>Ann Clin Lab Sci</source><year>2005</year><volume>35</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">16254261</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname><given-names>AE</given-names></name><name><surname>Blinder</surname><given-names>MA</given-names></name><name><surname>Gronowski</surname><given-names>AM</given-names></name><name><surname>Chumley</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>MG</given-names></name></person-group><article-title>Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations</article-title><source>Clin Chem</source><year>1998</year><volume>44</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">9550557</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labbe</surname><given-names>RF</given-names></name><name><surname>Vreman</surname><given-names>HJ</given-names></name><name><surname>Stevenson</surname><given-names>DK</given-names></name></person-group><article-title>Zinc protoporphyrin: a metabolite with a mission</article-title><source>Clin Chem</source><year>1999</year><volume>45</volume><fpage>2060</fpage><lpage>2072</lpage><pub-id pub-id-type="pmid">10585337</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>XM</given-names></name><name><surname>Ji</surname><given-names>CY</given-names></name><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Long</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>XY</given-names></name></person-group><article-title>Levels of serum transferrin receptor and its response to Fe-supplement in Fe-deficient children</article-title><source>Br J Nutr</source><year>2006</year><volume>96</volume><fpage>1134</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">17181889</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez Lopez</surname><given-names>MA</given-names></name><name><surname>Carracedo</surname><given-names>A</given-names></name><name><surname>Lendinez</surname><given-names>F</given-names></name><name><surname>Munoz</surname><given-names>FJ</given-names></name><name><surname>Lopez</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name></person-group><article-title>The usefulness of serum transferrin receptor for discriminating iron deficiency without anemia in children</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><fpage>264</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">16461317</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettmer</surname><given-names>RL</given-names></name><name><surname>Carlson</surname><given-names>TH</given-names></name><name><surname>Origenes</surname><given-names>ML</given-names></name><name><surname>Jack</surname><given-names>RM</given-names></name><name><surname>Labb</surname><given-names>RF</given-names></name></person-group><article-title>Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency</article-title><source>Pediatrics</source><year>1999</year><volume>104</volume><fpage>e37</fpage><pub-id pub-id-type="pmid">10469820</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>MA</given-names></name><name><surname>Luxton</surname><given-names>AW</given-names></name><name><surname>Walker</surname><given-names>WH</given-names></name></person-group><article-title>Serum ferritin concentration and bone marrow iron stores: a prospective study</article-title><source>Can Med Assoc J</source><year>1978</year><volume>118</volume><fpage>945</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">647567</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipschitz</surname><given-names>DA</given-names></name><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Finch</surname><given-names>CA</given-names></name></person-group><article-title>A clinical evaluation of serum ferritin as an index of iron stores</article-title><source>N Engl J Med</source><year>1974</year><volume>290</volume><fpage>1213</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">4825851</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname><given-names>FC</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Gottstein</surname><given-names>R</given-names></name><name><surname>Emmerson</surname><given-names>AJ</given-names></name></person-group><article-title>Is supplementary iron useful when preterm infants are treated with erythropoietin?</article-title><source>Arch Dis Child</source><year>2006</year><volume>91</volume><fpage>1036</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">17119084</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horl</surname><given-names>WH</given-names></name></person-group><article-title>Iron therapy for renal anemia: how much needed, how much harmful?</article-title><source>Pediatr Nephrol</source><year>2007</year><volume>22</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">17206511</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haiden</surname><given-names>N</given-names></name><name><surname>Schwindt</surname><given-names>J</given-names></name><name><surname>Cardona</surname><given-names>F</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Klebermass</surname><given-names>K</given-names></name><name><surname>Wald</surname><given-names>M</given-names></name><name><surname>Kohlhauser-Vollmuth</surname><given-names>C</given-names></name><name><surname>Jilma</surname><given-names>B</given-names></name><name><surname>Pollak</surname><given-names>A</given-names></name></person-group><article-title>Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B<sub>12</sub> on the transfusion requirements of extremely low birth weight infants</article-title><source>Pediatrics</source><year>2006</year><volume>118</volume><fpage>2004</fpage><lpage>2013</lpage><pub-id pub-id-type="pmid">17079573</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthington-White</surname><given-names>DA</given-names></name><name><surname>Behnke</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name></person-group><article-title>Premature infants require additional folate and vitamin B<sub>12</sub> to reduce the severity of the anemia of prematurity</article-title><source>Am J Clin Nutr</source><year>1994</year><volume>60</volume><fpage>930</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">7985636</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Diagnostic plot for identifying the different erythropoietic states with therapeutical implications for the treatment of different phases of iron deficiency adapted from Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>]. <sup>a</sup>Therapeutic implications for the treatment of different phases of iron deficiency according to Thomas et al. [<xref ref-type="bibr" rid="B11">11</xref>]</p></caption><graphic xlink:href="neo-0095-0164-g01"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Change in sTfR (a), ferritin index (b) and CHr (c) during the treatment by study group. Data are shown as mean &#x000b1; SEM. Post hoc statistical significance compared with group 1 is indicated by the asterisk(s): * p &#x0003c; 0.05; ** p &#x0003c; 0.01; ns = not significant.</p></caption><graphic xlink:href="neo-0095-0164-g02"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Diagnostic plot for identifying the different erythropoietic states. The course of each group is plotted from the 3-day run-in baseline period (day = &#x02212;3) through the start of treatment (day = 0) continuing on to the end of treatment (day = 18). The x-axis represents the biochemical indicators for iron supply (sTfR/log ferritin, i.e., ferritin index) and the y-axis represents the hematological indicator for iron demand by erythropoiesis (CHr). Q1-4 indicates quadrants 1 to 4.</p></caption><graphic xlink:href="neo-0095-0164-g03"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical data at birth, start of treatment and during treatment</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Study group</th><th align="left" rowspan="1" colspan="1">Oral iron</th><th align="left" rowspan="1" colspan="1">EPO + oral iron</th><th align="left" rowspan="1" colspan="1">EPO + IV iron</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">At birth</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Weight</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,021&#x000b1;84*</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">923&#x000b1;74</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,093&#x000b1;66</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.28</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">At start of treatment</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Age, days</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">27.2&#x000b1;4.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.1&#x000b1;3.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">23.3&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Weight</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,281&#x000b1;74</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,095&#x000b1;83</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,266&#x000b1;81</td><td align="left" rowspan="1" colspan="1">0.20</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Phlebotomy loss, ml/kg</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.5&#x000b1;5.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.3&#x000b1;3.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">10.6&#x000b1;2.0</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">During treatment</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Caloric intake, kcal/kg/day</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">111&#x000b1;3.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">109&#x000b1;4.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">106&#x000b1;3.6</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Weight gain, g/kg/day</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15.8&#x000b1; 1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">15.1&#x000b1;0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.0&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Weight at study exit, g</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,700&#x000b1;87</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,441&#x000b1;111</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,636&#x000b1;102</td><td align="left" rowspan="1" colspan="1">0.19</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Phlebotomy loss, ml/kg</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.9&#x000b1;0.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.8&#x000b1; 1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.3&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">0.05</td></tr></tbody></table><table-wrap-foot><fn><p>* Mean&#x000b1;SEM. All between-group comparisons demonstrated no statistically significant differences.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Study treatment groups</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Treatment modality</th><th align="left" rowspan="1" colspan="1">Group 1 oral iron</th><th align="left" rowspan="1" colspan="1">Group 2 EPO + oral iron</th><th align="left" rowspan="1" colspan="1">Group 3 EPO + oral + IV iron</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Oral iron, mg/kg/day</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">IV iron, mg/kg/day</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">EPO, U/kg/day</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">300</td><td align="left" rowspan="1" colspan="1">300</td></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of laboratory data at the start (day 0) and the end of treatment (day 18).</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Day</th><th align="left" rowspan="1" colspan="1">Oral iron (n = 9)</th><th align="left" rowspan="1" colspan="1">EPO + oral iron (n = 10)</th><th align="left" rowspan="1" colspan="1">EPO + IV iron (n = 10)</th><th align="left" rowspan="1" colspan="1">ANOVA p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">sTfR, mg/l</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.32&#x000b1;0.41</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.19&#x000b1;0.35</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.76&#x000b1;0.13</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.59&#x000b1;0.57</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.57&#x000b1;0.53</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6.69&#x000b1;0.71</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01<xref ref-type="table-fn" rid="T3F1"><sup>a</sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Ferritin, &#x003bc;g/l</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">309.8&#x000b1;32.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">380.9&#x000b1;72.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">352.4&#x000b1;55.4</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">171.2&#x000b1;35.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">233.1&#x000b1;43.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">852.1&#x000b1; 167.5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01 <xref ref-type="table-fn" rid="T3F2"><sup>b</sup></xref>, <xref ref-type="table-fn" rid="T3F3"><sup>c</sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Ferritin index</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.95&#x000b1;0.17</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.89&#x000b1;0.16</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.71&#x000b1;0.06</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.21&#x000b1;0.27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.50&#x000b1;0.32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.34&#x000b1;0.24</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05<xref ref-type="table-fn" rid="T3F1"><sup>a</sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">CHr, pg</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">27.6&#x000b1;0.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.0&#x000b1;0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">26.6&#x000b1;0.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.8&#x000b1;0.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">27.5&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05<xref ref-type="table-fn" rid="T3F4"><sup>d</sup></xref></td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Hb, g/l</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">112&#x000b1;3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">117&#x000b1;8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">115&#x000b1;5</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr valign="top"><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">92&#x000b1;3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">102&#x000b1;7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">113&#x000b1;6</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05<xref ref-type="table-fn" rid="T3F1"><sup>a</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>Values shown are mean&#x000b1;SEM. NS = Not significant.</p></fn><fn id="T3F1"><label>a</label><p>EPO + IV iron group and EPO + oral iron group compared with the oral iron group.</p></fn><fn id="T3F2"><label>b</label><p>EPO + IV iron group compared with the oral iron group.</p></fn><fn id="T3F3"><label>c</label><p>EPO + IV iron group compared with EPO + oral iron group.</p></fn><fn id="T3F4"><label>d</label><p>EPO + oral iron group compared with the oral iron group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>